A diagnostic imaging tool that measures the persistent reduction in connectivity between the anterior hippocampus and the default mode network to quantify the therapeutic 'window' of psychedelic treatment.
The PESTEL analysis reveals a high-potential opportunity driven by strong technological readiness and social demand, but significant headwinds in legal and political spheres. The success of the tool depends on the FDA's willingness to accept neuroimaging biomarkers as valid endpoints for psychedelic therapy approval.
Political2
Economic2
Social2
Technological2
Environmental1
Legal2
The viability of a psychedelic diagnostic tool is heavily dependent on FDA regulatory approval and the evolving legal status of controlled substances. · Generated 2026-09-07 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated